LONDON: British biopharmaceutical company Avacta Group Plc (AVCT.L) said on Monday it has raised approximately £16 million ($20.5 million) in an oversubscribed share placing, providing it with working capital to progress its cancer drug development programs into the second half of 2026. The company, which is developing targeted cancer therapies using its pre|CISION platform, placed…
WATERTOWN: EyePoint Pharmaceuticals, Inc. announced Monday it has commenced an underwritten public offering of $150 million of its common stock. The biopharmaceutical company, which focuses on treatments for serious retinal diseases, stated that all shares in the offering are being sold by the company. EyePoint also plans to grant the underwriters a 30-day option to…
LONDON, UK: AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. Under the terms of the agreement, AstraZeneca, through a subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding…
BERGEN, NORWAY: BerGenBio ASA, a clinical-stage biopharmaceutical company, announced today the appointment of Anders Tullgren to succeed Sveinung Hole as Chairman of the Board of Directors, effective Thursday. Sveinung Hole has been Chairman of the Board since March 2019 and will continue to serve as a Board Member. Anders Tullgren has over 35 years of…
PARIS, FRANCE: Inventiva, a clinical-stage biopharmaceutical company, has completed sales of 2.083 million American Depositary Shares (ADS) pursuant to the company’s ATM program established on August 2, 2021, through Jefferies LLC. Each American Depositary Shares (ADS) represents one ordinary share of the company. In the ATM sales, an aggregate of 2,083,334 new American Depositary Shares…
HENDERSON: Spectrum Pharmaceuticals Inc. intends to offer and sell shares of its common stock in an underwritten registered public offering, a news release said. All of the shares in the offering are to be sold by Spectrum. Spectrum also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of…